key TOPICS

NEW CONCEPTUAL MODELS OF ALZHEIMER’S DISEASE

• Promote the discovery of early markers in asymptomatic people at risk for dementia

• Explore new therapeutic targets for disease modification or prevention

• Identify new outcome measures for efficacy of disease modifying treatments 

INFRASTRUCTURE NEEDS FOR INTERNATIONAL PREVENTION TRIALS

• Harmonization of international, multicenters large-scale prevention trials

• Recruitment and retention of asymptomatic subject/volunteers for prevention trials

• International regulatory issues

METHODOLOGICAL ISSUES

• Assessing the impact of clinical trials on today’s medical practice

• Design of case report forms and other data-collecting methods for clinical trials

• General or specific designs and operating features for data processing systems used for maintaining databases clinical trials

• Management of multicenter investigations

• Methods for assessing patient's compliance

• Organizational structures for facilitating multicenter investigations

• Statistical methods for clinical trials

• Study design and clinical endpoints

PREVENTIVE AND DISEASE-MODIFYING TRIALS

• AD Primary Preventive Trials

• AD Secondary Preventive Trials

• AD Disease-modifying trials

• AD Symptomatic trials

• Trials in severe dementias

• Trials in other dementias : Parkinson dementia - Vascular dementia - Frontal dementia

VALIDATION OF BIOMARKER & CLINICAL OUTCOME MEASURES FOR PREVENTION TRIALS

• CSF biomarkers

• Neuroimaging biomarkers : MRI, fMRI, PETscan, SPECT...

• Plasma biomarkers

STATUS OF ONGOING CLINICAL TRIALS & UPDATES OF NEW THERAPIES

• Immunotherapies

• α and β secretase inhibitors